Collegium announces authorized generic agreement with Hikma for Nucynta, Nucynta ER

Collegium Pharmaceuticals has entered into an authorized generic agreement with Hikma, in which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta and Nucynta ER (“the Nucynta Franchise”) in the United States.

“Our agreement with Hikma bolsters the value of the Nucynta Franchise through 2025 and beyond,” said Joe Ciaffoni, president and CEO of Collegium. “Collegium is pleased to work with Hikma, an industry leader, to ensure that these important products continue to be manufactured to the highest quality standards and remain broadly and consistently accessible to appropriate patients.”

[Read more: Hikma intros Kloxxado]

Under the terms of the agreement:

• Collegium will manufacture and supply Hikma with all authorized generic product for sale on an exclusive basis during the term of the agreement.
• Hikma will sell the authorized generic forms of the Nucynta Franchise in the United States, commencing 30 days prior to the anticipated loss of exclusivity for each product, or earlier under certain circumstances.
• Collegium will receive a meaningful share of net profits of the authorized generic products, that declines based on the number of generic entrants, if any.

[Read more: Hikma, FAES Farma ink licensing agreement for Bilastine]